Novel Technologies

Unlocking Hemophilia

The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.

Novel Technologies

Six at a Time

Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.

Novel Technologies

FVII Gene Therapy Trial in Dogs; New FIX and HCV Drugs

An update on FVII gene therapy and more.

Novel Technologies

FDA in Action

Updates on Daklinza, Technivie, and the ACE910 trial

Novel Technologies

Finger pointing at March 14, 2014 on calendar

Home Stretch

There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval...

Novel Technologies

Wave of Progress

Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for...

Novel Technologies, Hemophilia A&B

CDC’s Inhibitor Risk Study

A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused...

Novel Technologies

Delivery person with dolly and stacked boxes

Package Deal

Update, November 2014: The St. Jude/UCL gene therapy trial now has data from all 10 participants, to be published in...

Novel Technologies, Hemophilia A&B

Progress Made for My Life, Our Future Genotyping Initiative

Five pilot sites have been approved and first patients enrolled

Novel Technologies

Genotyping for Progress

During the past 20 years, advances in hemophilia treatment, including recombinant factor therapy, have allowed people with hemophilia to take...

Novel Technologies, Hemophilia A&B

How Modern Medicine Has Tackled HIV

Update, August 2013: The FDA approved Tivicay® (dolutegravir), manufactured by ViiV Healthcare, a GlaxoSmithKline company. Tivicay is an integrase strand...

HIV, Novel Technologies

Pondering Prophylaxis

For Christine Orr, the trigger for starting prophylaxis wasn’t just one thing. It was everything. Orr’s son, John, diagnosed with...

Family Matters